DSIP

DSIP’s name reflects an early hypothesis about sleep. It does not mean the peptide reliably induces delta sleep or treats insomnia. The original chemical characterization identified the nine-residue sequence in rabbit experiments (PMID 265572). A later review questioned whether DSIP itself is an endogenous sleep factor and described the evidence for that role as weak (PMID 16539679).

What have human sleep studies found?

An early experiment in six healthy volunteers reported changes in daytime and subsequent night sleep after intravenous DSIP (PMID 6895513). Another six-person study in chronic insomnia reported longer and less interrupted sleep (PMID 7028502). Later reports from the same research group described improvements in groups of 18 and 14 people with chronic insomnia (PMID 3792404; PMID 3622582). A 1983 paper summarizes five human studies; it must not be counted as five additional independent trials or participants (PMID 6689058).

The results did not replicate consistently. A double-blind crossover study by Monti and colleagues found that apparent sleep changes were of little clinical significance (PMID 3583493). A separate double-blind, placebo-controlled study of 16 people with chronic insomnia found weak objective signals, no improvement in subjective sleep quality, and concluded that short-term DSIP was unlikely to provide major therapeutic benefit (PMID 1299794). FDA’s 2026 review judged the overall intravenous insomnia evidence inconclusive and found no effectiveness study for the proposed subcutaneous route (FDA emideltide briefing, pp. 24–31). These findings do not justify a claim that DSIP normalizes sleep in people.

What do the other findings mean?

In rats, one experiment linked DSIP-related sleep signs to a response blocked by the serotonin antagonist methysergide; that is a mechanistic clue, not a validated human treatment pathway (PMID 6132892). A rabbit study found altered EEG activity (PMID 265572), while another study found no statistically significant sleep effect of the parent DSIP in rabbits even though some analogues did affect sleep (PMID 11525128).

Other animal experiments reported mitochondrial changes during hypoxia and altered oxidative markers during cold stress (PMID 12668217; PMID 11421812). Centrally administered DSIP changed pain-response tests in mice and rats; naloxone blocked that effect (PMID 2853064). None of those experiments establishes a sleep, pain, or stress-protection benefit in humans. In a separate 11-person human crossover study, ACTH-like immunoreactivity fell after intravenous DSIP, while plasma and urinary cortisol did not change; this was a hormone-marker study, not evidence of an insomnia or stress treatment (PMID 2554357).

Regulatory and safety context

FDA’s July 2026 briefing proposed against adding emideltide free base and acetate to the 503A bulks list, citing limited effectiveness and safety information and product-characterization concerns. It found no safety data for the proposed subcutaneous route. That proposal should not be described as a final rule or an approval (FDA briefing, pp. 52–55; FDA meeting page). The available studies also do not establish whether DSIP can be combined safely with Selank, Semax, Epithalon, melatonin, or other products.

This page summarizes research for education. It does not provide treatment, dosing, product-quality, or purchasing guidance.